Peptide safety: risks shared across compounds

Approved vs. unapproved: the evidence gap

Approved peptide drugs such as semaglutide or tesamorelin have been tested in controlled clinical trials, and their known risks appear on their labels. Many popular "wellness" peptides have not. For several of them FDA has stated it has little or no human safety data for the routes people use ¹. For BPC-157, for example, published human data consist of a handful of small or unpublished studies, including a two-person intravenous pilot; reviewers conclude this does not meet the standard for establishing safety and effectiveness ⁵. "No reported problems" is not the same as "proven safe," especially for long-term use.

Contamination, endotoxin, and infection

Injectable products bypass the skin and gut barriers that normally protect the body from microbes and toxins ⁹. Risks include:

Endotoxin: found in all three gray-market semaglutide vials in one 2024 test-purchase study ²; endotoxin-contaminated compounded glutathione injections sickened more than two dozen people in 2026 ⁴.
Injection-site infections and abscesses, especially with non-sterile products or reused materials.
Wrong or extra ingredients: one product sold as growth hormone in Australia contained insulin ³.

Immunogenicity and anti-drug antibodies

The immune system can recognize a peptide, or its impurities and aggregates, as foreign and produce anti-drug antibodies. Consequences range from loss of effect to allergic reactions, and in theory antibodies could cross-react with the body's own related hormone. Immunogenicity risk is the most common concern FDA lists for the peptides it placed in Category 2 ¹.

Growth factors and theoretical cancer concerns

Peptides that raise growth hormone and IGF-1 (GHRH analogs, GH secretagogues), or that promote angiogenesis (new blood-vessel growth), act on pathways that help tissues grow and repair. The same pathways can, in principle, support the growth of existing tumors. This is a theoretical concern rather than an established effect for most of these compounds, but long-term studies are lacking. Reviewers of BPC-157, for instance, describe its pro-angiogenic signaling as a "plausible tumor-promoting hazard" not ruled out by current data ⁵. FDA's review of Melanotan II cites case reports of melanoma ¹. People with a history of cancer should be especially cautious and discuss any growth-related peptide with an oncologist.

Interactions and other medical conditions

Peptides can interact with medicines and conditions in ways that are poorly studied. Examples: GLP-1 drugs slow stomach emptying, which can alter absorption of oral medications and raises anesthesia-aspiration concerns; GH-axis peptides can raise blood glucose; melanocortin peptides can raise blood pressure. Anyone taking prescription medications, or with diabetes, heart, kidney, liver or psychiatric conditions, should review any peptide with a clinician.

Pregnancy and breastfeeding

Most unapproved peptides have no human pregnancy or lactation data at all, and some approved peptides (including GLP-1 drugs) carry advice to stop before a planned pregnancy. Avoid unapproved peptides when pregnant, trying to conceive, or breastfeeding, and discuss approved ones with an obstetric provider.

Athletes and drug testing

Many peptides are prohibited at all times under the WADA Code, including BPC-157 (S0), GH secretagogues, GHRH analogs, TB-500 and IGF-1 (S2), and MOTS-c (S4) ⁶. Because gray-market products are frequently mislabeled ³, an athlete can also test positive for a substance not listed on the vial.

Reporting problems and getting help

Emergency: call 911 for trouble breathing, swelling of the face or throat, chest pain, fainting, severe abdominal pain, or signs of a spreading infection.
Poison Help line (U.S.): 1-800-222-1222, free and confidential, 24/7 ⁸.
Report adverse events or bad products to FDA MedWatch: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program ⁷. Reports help FDA spot contaminated or counterfeit products.

When to see a doctor

See a clinician before starting any peptide, and promptly if you notice redness, warmth or pus at an injection site, fever or chills, persistent nausea or vomiting, severe abdominal pain, unusual swelling, rapid heartbeat, vision changes, new or changing moles, or symptoms of low blood sugar (shakiness, sweating, confusion). Bring the product and its packaging so the clinician knows what was used.

Peptide Safety: Cross-Cutting Risks